Notable Labs

Notable Labs ROCE

The Return on Capital Employed (ROCE) of Notable Labs (NTBLQ) as of Nov 8, 2026 is -96.98 %. In the previous year, Return on Capital Employed (ROCE) was -146.33 % — a change of -33.73% (higher).

ROCE

-96.98 %

YoY

-33.73%

Last updated:

In 2023, Notable Labs's return on capital employed (ROCE) was -96.98 %, a -33.73% increase from the -146.33 % ROCE in the previous year.

The Notable Labs ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2016
-38.40 USD
Jan 1, 2017
-19.07 USD
Jan 1, 2018
-40.03 USD
Jan 1, 2019
-55.73 USD
Jan 1, 2020
-79.17 USD
Jan 1, 2021
-57.49 USD
Jan 1, 2022
-146.33 USD
Jan 1, 2023
-96.98 USD
The Notable Labs ROCE history
YEARROCEYoY
-96.98 %-33.73%
-146.33 %+154.51%
-57.49 %-27.38%
-79.17 %+42.06%
-55.73 %+39.24%
-40.03 %+109.89%
-19.07 %-50.33%
-38.40 %-9.60%
-42.47 %+0.87%
-42.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Notable Labs's Return on Capital Employed (ROCE)

Notable Labs's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Notable Labs's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Notable Labs's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Notable Labs’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Notable Labs stock

Return on Capital Employed (ROCE) of Notable Labs is -96.98 % in 2023.

Return on Capital Employed (ROCE) of Notable Labs changed from -146.33 % to -96.98 %, representing a -33.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Notable Labs

All Key Metrics — Notable Labs